New pill aims to extend remission in rare blood cancer
NCT ID NCT07347288
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called SHR2554 as a maintenance therapy for people with peripheral T-cell lymphoma who have responded to initial treatment. The goal is to see if taking this pill can help keep the cancer from progressing for longer. About 30 adults who have achieved complete or partial remission after first-line therapy will take SHR2554 and be monitored for side effects and disease control.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTCL are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital with Nanjing Medical University
Nanjing, Jiangsu, 210000, China